Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
September 19 2024 - 7:00AM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces its participation in the
Annual Scientific Meeting of the Heart Failure Society of America
(HFSA), taking place September 27-30 at the Georgia World Congress
Center and Signia by Hilton Atlanta. The event will gather the
world’s top heart failure experts.
Key meeting highlights:
- Exclusive showcase of BVA at the
HFSA 'Devices in Heart Failure: From Mechanisms to Implementation'
session.
- Presentation of products and
services in the main Exhibit Hall.
- Corporate Member Meeting with HFSA
leadership.
“We're excited to showcase how our BVA
technology provides precise, actionable data, enabling clinicians
to personalize treatment for both inpatient and outpatient care,"
said Michael Feldschuh, CEO and President of Daxor Corporation. "By
equipping healthcare providers with innovative diagnostic tools for
informed decision-making, we aim to enhance patient outcomes and
drive long-term improvements in heart failure treatment and reduce
overall costs."
BVA guided treatment in heart failure has shown
to reduce heart failure 30-day readmissions by 56%, 30-day
mortality by 82%, 1-year mortality by 86% and results in a 57%
reduction in length of stay when done on admission
(P<0.001).
The company will be exhibiting at Booth 225.
Register for HFSA2024.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Nov 2023 to Nov 2024